Uttar Pradesh Association of Physicians of India Position Statement: Betel Quid (Paan) and Diabetes

Yatan Pal Singh Balhara1, Sanjay Kalra2, Sarita Bajaj3, Pooja Patnaik Kuppili4, D Himanshu5, Veerendra Atam6, Kauser Usman7, Veerendra Singh8, Shyam Chand Chaudhary9, S Chakravorty10, Anupam Wakhlu11, Jalees Fatma12, Sanjay Tandon13, Anuj Maheshwari14, Abha Gupta15, Anjum Parvez16, Jaya Chakravarty17, RR Chaudhary18, AK Singh19, KK Sawlani20, Manoj Mathur21, NK Soni22, Om Kumari Gupta23, Madhukar Rai24, Sudhir Agarwal25

Abstract
Betel quid (paan) chewing is common in India, especially in Uttar Pradesh. Betel quid has multifaceted relationship with health, including metabolic and psychosocial health. The current recommendations have been released keeping in view the public health and clinical importance of this addictive behavior. The objective of this document is to offer clinical guidance for screening, diagnosis and management of co-occurring betel quid chewing among persons with Diabetes Mellitus (DM). The document aims to provide education and guidance to clinicians engaged in care and management of persons with DM, and improve access to treatment for co-occurring betel quid chewing among persons with DM. The current recommendation grades are based on published evidence, and categorized as strong, intermediate, weak and no evidence. The strength of these recommendations is based on the level of evidence.

Scope and Purpose
Betel quid (paan) chewing is common in India, especially in Uttar Pradesh. Betel quid (paan) has multifaceted relationship with health, including metabolic and psychosocial health. The Indian College of Physicians Position Statement on Addictive disorders among persons with diabetes (2017)1 have addressed this important aspect of health and clearly advise against betel quid (paan)-chewing. A grade 3B evidence/ recommendation is given to this statement.

The current recommendations have been released keeping in view the public health and clinical importance of this addictive behavior. The objective of this document is to offer clinical guidance for screening, diagnosis and management of co-occurring betel quid (paan) chewing among persons with Diabetes Mellitus (DM). The document aims to provide education and guidance to clinicians engaged in care and management of persons with DM, and improve access to treatment for co-occurring betel quid chewing among persons with DM.

Grading of Evidence
The current recommendation grades are based on published evidence, and categorized as strong, intermediate, weak and no evidence. The strength of these recommendations is based on the level of evidence. The categories of the level of evidence and strength of recommendation are listed in Tables 1 and 2, respectively. The American

Table 1: Evidence level used for rating various recommendations

<table>
<thead>
<tr>
<th>Evidence level</th>
<th>Evidence rating</th>
<th>Methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Strong</td>
<td>Meta-analysis of randomized controlled trials</td>
</tr>
<tr>
<td>2</td>
<td>Intermediate</td>
<td>Randomized controlled trials</td>
</tr>
<tr>
<td>3</td>
<td>Weak</td>
<td>Meta-analysis of non randomized prospective or case-controlled trials, systemic literature review</td>
</tr>
<tr>
<td>4</td>
<td>No evidence</td>
<td>Non randomized controlled trials</td>
</tr>
</tbody>
</table>

1Associate Professor of Psychiatry, National Drug Dependence Treatment Center and Department of Psychiatry, AIIMS, Delhi; 2Consultant, Department of Endocrinology, BHRI, Hospital and BRIIDE, Karnal, Haryana; 3Consultant Endocrinologist, Director-Professor and Head, Dept of Medicine, MLN Medical College, Allahabad, Uttar Pradesh; 4Senior Resident, Department of Psychiatry, JIPMER, Puducherry; 5Professor and Head, Department of Medicine, KMGMU Lucknow, Uttar Pradesh; 6Professor, Department of Medicine, KMGMU Lucknow, Uttar Pradesh; 7Consultant Physician, Faizabad, Uttar Pradesh; 8Additional Professor, Dept of Medicine, KMGMU Lucknow, Uttar Pradesh; 9Sr. Consultant Physician and Unit Head, Department of Internal Medicine, Diabetology and Critical Care, Metro Multispeciality Hospital, Noida, Uttar Pradesh; 10Professor, Department of Rheumatology, KMGMU Lucknow, Uttar Pradesh; 11Professor and Head, Department of Medicine, Era’s Lucknow Medical College, Lucknow, Uttar Pradesh; 12Diabetologist and Metabolic Physician, Professor and Head in Internal Medicine, BBD CODS, BBD University, Lucknow, Uttar Pradesh; 13Consultant Physician, Former Associate Prof and Head, Dept. of Medicine, AIIMS, Lucknow, Uttar Pradesh; 14Professor, Dept. of Medicine, LLRM Medical College, Meerut, Uttar Pradesh; 15Professor, Dept. of Medicine, NH Medical College, AMU, Aligarh, Uttar Pradesh; 16Professor, Dept. of Medicine, IMS, BHU, Varanasi, Uttar Pradesh; 17Senior Consultant Physician & Geriatrician, S.S.P.G. Divisional District Hospital, Varanasi, Uttar Pradesh; 18Associate Professor, Department of Medicine, MLN Medical College, Allahabad, Uttar Pradesh; 19Consultant Physician, Ghaziabad, Uttar Pradesh; 20Sr. Consultant and Clinical Hematologist, Metro Heart and Research Institute, Noida, Uttar Pradesh; 21Consultant Physician, Saharanpur, Uttar Pradesh; 22Associate Professor, Dept. of Medicine, MLN Medical College, Allahabad, Uttar Pradesh; 23Consultant Physician, Ghaziabad, Uttar Pradesh; 24Sr. Consultant and Clinical Hematologist, Metro Heart and Research Institute, Noida, Uttar Pradesh; 25Consultant Physician, Saharanpur, Uttar Pradesh.

Received: 06.06.2017, Accepted: 10.10.2017
Association of Clinical Endocrinologists has used such an approach previously. Most recommendations are extrapolated from literature on substance use disorder, as limited literature exists about DM comorbid with addictive (substance use) disorders. It must be noted that different evidence levels can be mapped to the same recommendation grade by ‘adjusting up’ or ‘adjusting down’ depending on the importance and relevance based on expert opinion.

**Epidemiology**

Betel quid is perhaps the fourth most popular psychoactive substance in the world, after caffeine, nicotine and alcohol. At least 600 million people worldwide chew betel quid. Uttar Pradesh reports a high consumption rate of betel quid chewing, especially in studies on persons with oral malignancy.

Betel quid has a few core constituents (areca nut (supari), betel leaf (paan ka patta), slaked lime (chuna) and tobacco), though other ingredients may be added as per preference. These include aniseed, cardamom, rose petal preserve and catechu (katha) (Table 1). The term ‘sweet paan’ or ‘meetha paan’ is used to describe a tobacco-less variant of betel quid, in which the sweet flavor is derived from these spices. However, it does contain other ingredients including areca nut (commonly called geele supari).

**Betel Quid Dependence**

Betel quid use can be associated with a level of addiction or dependence that is similar to that of other psychoactive substances. Tobacco (smokeless form) present in betel quid is a psychoactive substance with well-accepted addictive properties. Apart from and independent of presence of tobacco, betel quid does have psychoactive properties owing to the presence of areca nut. It has clearly been shown that addictive potential of areca nut is not based upon simultaneous use of tobacco in the mixture. Additionally, areca nut has been established as a proven carcinogen.

Areca contains 4 main alkaloids: arecoline, arecaidine, guvacine, and guvacoline. These alkaloids create a sense of alertness and wellbeing, by binding to GABA receptors.

The Betel Quid Dependence Scale, developed and tested in Taiwan and Guam, has been validated to measure betel quid dependence. It assesses three domains: ‘physical and psychological urgent need’ (7 item) ‘increasing dose’ (5 items), and ‘maladaptive use’ (4 items). Persons who practiced addiction of tobacco to the betel quid mixture, and who reported a greater frequency of chewing, or a longer period of chewing, were found to have greater dependence on betel quid.

**Adverse Effects**

**Cancer**

Betel quid has been classified as a Group I carcinogen by the International Agency for Research on Cancer. It is linked to cancer of oral cavity, pharynx, esophagus, liver, biliary tract and uterus.

**Metabolic Syndrome**

Betel quid has adverse effects on metabolic health. Betel nut contains nitrosated derivatives of arecal alkaloids. Apart from their psychoactive and tumorigenic effects, they are shown to have diabetogenic and obesogenic effects in animal as well as clinical studies.

The Taiwan Longitudinal Survey on Aging has shown that past betel quid chewing is positively associated with new onset diabetes in Taiwanese adults aged 53 years or more. In a community-based study of 993 ‘healthy’ Bangladeshis living in east London, betel nut consumption was associated with increased waist size in both men and women; and increased glucose levels in women. A met analysis of 17 Asian studies (5 cohort studies, 12 case control studies), including 388134 participants has shown an increased risk of obesity (adjusted relative risk [aRR] 1047; p < 0.001); metabolic syndrome (aRR 1051; p = 0.01), diabetes (aRR 1.47, p < 0.001), hypertension (aRR 1.45, p = 0.06), cardiovascular disease (aRR 1.2, p = 0.02), and all-cause mortality (aRR 1.21, p = 0.02), with betel quid chewing. Various mechanisms of action have been proposed to explain the metabolic effects of betel quid. These are listed in Table 3.

**Renal Disorders**

A small study of eight patients proposed that betel quid chewing may predispose to urinary stone disease, perhaps because of the high intake of slack line. A retrospective review of charts of Taiwanese 3264 men has shown a higher prevalence of chronic kidney disease in betel nut users (adjusted odds ratio 2.572, 95% CI 1.917-3.451). This association is independent of other factors including smoking, alcohol use, and diabetes.

**Vitamin D Levels**

Betel nut chewing may contribute to hypovitaminosis D. In a pilot study conducted among 33 healthy British Bangladeshis, serum 1, 25 dihydroxy vitamin D showed an inverse correlation with betel quid chewing. Betel chewing, therefore, could aggravate the metabolic effects of vitamin D deficiency.

**Infectious Disease**

In Cambodia, Betel quid use is associated with an increase in risk of infectious disease, including HIV/AIDS, dengue fever, tuberculosis and typhoid, especially in women. It is postulated that betel quid chewing may increase propensity to infection by immunosuppression, injury to the oral mucosa (facilitating oral entry pathogens) or faeco-oral contamination of its ingredients.

**Mortality**

A Bangladeshi cohort study-carried
out among 20033 adults living in Araihazar, over 10 years, has shown a greater risk of all-cause mortality and cancer-related mortality (HR 1.55, 95% CI hazard ratio (HR) 1.26; 95% confidence interval (CI) 1.09-1.44) (1.09-2.22), with betel quid chewing. There was no correlation of betel quid chewing with cardiovascular disease (HR 1.16; 95% CI 0.93-1.43). The duration and intensity of betel quid use demonstrated a dose-response relationship with all-cause mortality. The population attributable fraction for betel use was 14.1% for all-cause mortality, and 24.2% for cancer.\(^{24}\)

**Transgenerational Impact**

There is evidence that betel nut consumption during pregnancy may have adverse effects on birth weight, newborn neurological status and pregnancy outcome.\(^{25}\) A community-based screening programme from Taiwan reports that longer duration and earlier onset of paternal betel chewing and smoking may increase the risk of metabolic syndrome in offspring, independent of each other.\(^{26}\)

**Uttar Pradesh (UP) Association of Physicians of India (API) Recommendations**

Based upon the data presented above, the UP API suggests the following:

1. All persons with diabetes should be screened for betel quid use and dependence (Grade A, EL 2).

2. All persons using betel quid should be counselled to stop (Grade A, EL 2).

3. All persons not using betel quid should be counselled not to begin (Grade A, EL 2).

4. All persons dependent upon betel quid should be offered appropriate non-pharmacological therapy (Grade A, EL 4).

5. All persons dependent upon betel quid, especially with evidence of metabolic or health impairment due to this, should be referred to a qualified mental health specialist for further management (Grade A, EL 4).

6. All persons using betel quid, with comorbid conditions or complications, should be referred to appropriate health care providers (Grade A, EL 4).

7. Public health campaigns to limit the use of betel quid must be promoted and encouraged (Grade A, EL 4).

8. Research must be promoted to create validated betel quid dependence scales in Hindi and Urdu, and to assess various deaddiction strategies (Grade A, EL 4).

**References**


19. Balhara et al. Accepted in JPIA


